SBRT May Beat Brachytherapy in Prostate Cancer

Published Date: 27 Feb 2026

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

Read Full News

Latest News

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Belgian Algorithm Reshapes Endometrial Cancer Care

A new Belgian algorithm may help clinicians choose adjuvant therapy more precisely in early endometrial cancer, moving beyond TNM staging alone.

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Todays Updates

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Can a Betting Market Offer Hope to a Cancer Patient?

As we embrace the power of collective knowledge, we must remember that numbers are just numbers

Rewriting the Future of Medicine; Cancer Cost Burden; Mental Health Toll of Cancer

News, features, and commentary about cancer-related issues

Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test

News, features, and commentary about cancer-related issues

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

"This specific formulation of daunorubicin and cytarabine is not the right choice," experts said

Post-Transplant Outcomes in Hodgkin Lymphoma Improved Over Time

Improvements primarily driven by reduction in incidence of relapse

Todays Updates

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Can a Betting Market Offer Hope to a Cancer Patient?

As we embrace the power of collective knowledge, we must remember that numbers are just numbers

Rewriting the Future of Medicine; Cancer Cost Burden; Mental Health Toll of Cancer

News, features, and commentary about cancer-related issues

Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test

News, features, and commentary about cancer-related issues

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

"This specific formulation of daunorubicin and cytarabine is not the right choice," experts said

Post-Transplant Outcomes in Hodgkin Lymphoma Improved Over Time

Improvements primarily driven by reduction in incidence of relapse

Latest News

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

A new Belgian algorithm may help clinicians choose adjuvant therapy more precisely in early endometrial cancer, moving beyond TNM staging alone.

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

News All Time

Stem Cell Transplant Linked to Longer Survival in CMML

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Gatekeeping May Reduce Pediatric Cancer Trial Participation

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

AI Framework Helps Classify Renal Tumors, Predict Outcomes

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Dual Checkpoint Blockade Boosts Breast Cancer pCR

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

Breast Density Laws Fall Short Raising Additional Screening

State mandates requiring insurance coverage for additional breast cancer scans for those with dense breasts are failing to boost usage.

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

A trial tests whether 40Gy in 15 fractions over 3 weeks leads to more arm lymphedema than 50Gy in 25 fractions over 5 weeks.

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

Medicare coverage of next-generation sequencing may have spurred an increase in the number of patients receiving genomic tests. But uptake remains low.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Transperineal Biopsy IDs Active Surveillance Candidates

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

The Clues Hidden in Failed Prostate Cancer Trials

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

Recommended News For You

Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

Early, virtual palliative care feasible for advanced lung cancer

Coffee and tea linked to lower head and neck cancer risk

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

MGRS Relapse-Free Survival Better With Maintenance Therapy

Radiation from CT scans could account for 5% of all cancer cases a year, study suggests

Recommended Articles For You

Practical Applications in Hematology Across Clinical Settings 

Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control 

CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target 

Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

2.

New drug combination shows good results in patients with HPV-negative head and neck cancer

3.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

4.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

5.

Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant

1.

Environmental Carcinogen Exposure Screening: Advances, Clinical Implications, and Guideline-Based Approaches

2.

A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies 

3.

Progressive Insights in Hematology in the Digital Era

4.

Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations

5.

The importance of understanding normal serum osmolality

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

2.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

3.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot